Stay updated on DARZALEX in Indian MM Patients Clinical Trial

Sign up to get notified when there's something new on the DARZALEX in Indian MM Patients Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DARZALEX in Indian MM Patients Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:53:36.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety and effectiveness study of DARZALEX (Daratumumab) in Indian participants with relapsed and refractory multiple myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:41.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants with relapsed and refractory multiple myeloma, specifying inclusion and exclusion criteria, whereas previously it stated 'No information provided'.
    Difference
    24%
    Check dated 2024-05-22T21:01:23.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:32:23.000Z thumbnail image

Stay in the know with updates to DARZALEX in Indian MM Patients Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DARZALEX in Indian MM Patients Clinical Trial page.